Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease

Author:

Herrup Karl1,Carrillo Maria C.2,Schenk Dale3,Cacace Angela4,DeSanti Susan5,Fremeau Robert6,Bhat Ratan7,Glicksman Marcie8,May Patrick9,Swerdlow Russell10,Van Eldik Linda J.11,Bain Lisa J.12,Budd Samantha7

Affiliation:

1. Hong Kong University of Science and TechnologyDivision of Biology Life ScienceHong Kong

2. Alzheimer's AssociationDivision of Medical & Scientific RelationsChicagoILUSA

3. Elan Pharmaceuticals, Inc., Neotope BiosciencesSouth San FranciscoCAUSA

4. Bristol Myers Squibb, Research & DevelopmentWallingfordCTUSA

5. General Electric Healthcare, Medical DiagnosticsWaukeshaWIUSA

6. Amgen, Inc.Department of NeuroscienceCambridgeMAUSA

7. AstraZeneca, Neuroscience iMedCambridgeMAUSA

8. LDDNHarvard Medical SchoolMAUSA

9. Eli Lilly & Co., Inc.Lilly Research LaboratoriesIndianapolisINUSA

10. University of Kansas Medical CenterDepartment of NeurologyKansas CityKSUSA

11. University of Kentucky, Sanders‐Brown Center on AgingLexingtonKYUSA

12. PhiladelphiaPAUSA

Funder

NIH

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3